Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Cell Reports|August 17, 2022
Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironmentAthanasios Papadas, Gauri Deb, Alexander Cicala, et al.Cancers|May 27, 2026
Organoid Level Assessments of Human Primary and Metastatic Colorectal Cancer-Derived Organoids Predict Response to Chemotherapy and ChemoradiationShirsa Udgata, Alexa E Schmitz, Amani A Gillette, et al.Cancer Reports (Hoboken, N.J.)|July 10, 2021
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacyAlyssa A Leystra, Brock J Gilsdorf, Amanda M Wisinger, et al.Frontiers in Oncology|June 6, 2020
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug TreatmentJoe T Sharick, Christine M Walsh, Carley M Sprackling, et al.JCO Precision Oncology|September 11, 2020
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor BoardMark E Burkard, Dustin A Deming, Benjamin M Parsons, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.Molecular Cancer Therapeutics|November 15, 2018
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant CancersStephanie L Fricke, Susan N Payne, Peter F Favreau, et al.British Journal of Cancer|April 5, 2019
Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutationsJai-Hee Moon, Seung-Woo Hong, Jeong Eun Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Tumor matrix proteoglycan accumulation and processing alters T cell effector function and the response to immunotherapy in patients with oligometastatic colorectal cancerDustin A Deming, Sean G Kraus, Joshua Brand, et al.Pageof 8